What Results Can You Expect After Peptide Therapy for Menopause at Hortman Clinics
Health authority regulations in the US and Europe require pharmaceutical companies to conduct a pre-approval trial showing at least non-inferiority of cardiovascular (CV) safety compared with placebo treatment, for any new therapy to treat type 2 diabetes (T2D), prior to granting market approval
Cardiovascular Diabetology, 35(4), 178-185
After that, the protocol can often shift to a lower-frequency maintenance schedule to sustain the results
The peptide contains two non-natural amino acids (-amino isobutyric acids, Aib) at positions 2 and 13
These medications, known as GLP-1 receptor agonists (GLP-1-RAs), offer promising therapeutic options for type 2 diabetes and obesity-related conditions, including cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD) (6)